Cholangiocarcinoma (CCA) is a common malignancy of the digestive system, and its treatment is greatly challenged by rising chemoresistance. Long non-coding RNAs (lncRNAs) have been shown to play critical roles in the development of drug resistance in tumors. However, the role of the lncRNA CCAT1 in erlotinib resistance in CCA remains unclear. In this investigation, we identified CCAT1 as a pivotal factor contributing to erlotinib resistance in CCA. Furthermore, we uncovered that lncRNA CCAT1 modulated epithelial-mesenchymal transition (EMT) through Rho-associated coiled-coil-forming protein kinase 2 (ROCK2), thereby conferring erlotinib resistance upon CCA cells. Mechanistically, we demonstrated that miR-181a-5p interacted with CCAT1 to modulate the expression of ROCK2. Collectively, these findings shed light on the significant role of CCAT1 in the development of erlotinib resistance in CCA. The functional suppression of CCAT1 holds promise in enhancing the sensitivity to erlotinib by reversing EMT through the miR-181a-5p/ROCK2 signaling pathway. These findings provide valuable insights into the mechanisms underlying erlotinib resistance in CCA and the potential strategies for its treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236789 | PMC |
| http://dx.doi.org/10.62347/EQDK1844 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhibiting FGFR by toadflax reverses erlotinib resistance in nonsmall cell lung cancer.
Anticancer Drugs
August 2024
Department of Thoracic Surgery, Peking University Cancer Hospital Inner Mongolia Hospital.
This study aims to demonstrate the effect of toadflax (bufalin) on erlotinib resistance in nonsmall cell lung cancer (NSCLC) by inhibiting the fibroblast growth factor receptor (FGFR). The microfluidic mobility transferase and caliper mobility-shift assays were employed to detect the FGFR inhibition by bufalin and the binding reversibility. Further, the inhibitory effects of bufalin were determined in HCC827 and HCC827/ER cells in vitro, investigating relative FGFR overexpression by quantitative reverse transcriptase-PCR (RT-qPCR) and FGFR downstream proteins, that is, FGFR substrate 2 (FRS2), extracellular signal-regulated kinase (ERK), and S6 by western blot analysis.
View Article and Find Full Text PDFPotential Drug Synergy Through the ERBB2 Pathway in HER2+ Breast Tumors.
Int J Mol Sci
November 2024
Computational Genomics Division, National Institute of Genomic Medicine, Mexico City 14610, Mexico.
HER2-positive (HER2+) breast cancer is characterized by the overexpression of the ERBB2 (HER2) gene, which promotes aggressive tumor growth and poor prognosis. Targeting the ERBB2 pathway with single-agent therapies has shown limited efficacy due to resistance mechanisms and the complexity of gene interactions within the tumor microenvironment. This study aims to explore potential drug synergies by analyzing gene-drug interactions and combination therapies that target the ERBB2 pathway in HER2+ breast tumors.
View Article and Find Full Text PDFFluorinated Sulfonamides: Synthesis, Characterization, In Silico, Molecular Docking, ADME, DFT Predictions, and Structure-Activity Relationships, as Well as Assessments of Antimicrobial and Antioxidant Activities.
Drug Dev Res
December 2024
Chemistry Department, Faculty of Science (Boys), Nasr City, Al-Azhar University, Cairo, Egypt.
The design and synthesis of unique two series of fluorinated sulfonamides 3a-f and 5a-g utilizing nucleophilic aromatic substitution reactions of tetrafluorophthalonitrile 1 with various sulfonamides 2 under a variety of different reactions conditions were the key goals of the current research. The chemical composition of the generated products has been investigated via mass spectroscopy, HNMR, CNMR, infrared, and elemental analyzes. Antimicrobial studies were conducted in vitro to evaluate the activity of all new synthesized compounds against resistant strains.
View Article and Find Full Text PDFReal-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study.
Thorac Cancer
December 2024
Department of Chemotherapy, Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan.
Introduction: First-line osimertinib is widely used to treat patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancers (NSCLC). In clinical practice, rechallenge therapy with another EGFR-tyrosine kinase inhibitor (TKI) is often performed after first-line TKI discontinuation owing to resistance or toxicity; however, the efficacy and toxicity of EGFR-TKI rechallenge after first-line osimertinib have not been adequately investigated. This study aimed to examine the efficacy and safety of EGFR-TKI rechallenge with another TKI.
View Article and Find Full Text PDFMachine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth.
Cell Commun Signal
December 2024
International Research Centre for Food and Health, College of Food Science and Technology, Shanghai Ocean University, Shanghai, 201306, China.
Article Synopsis
- The study focuses on overcoming drug resistance in non-small cell lung cancer (NSCLC) patients due to the EGFR T790M mutation, which often develops during erlotinib treatment, by using advanced machine learning to identify new selective inhibitors.
- An integrated machine learning approach screened over 70,000 molecules, ultimately identifying CDDO-Me as an effective inhibitor that selectively binds to the mutated EGFR.
- CDDO-Me was shown to induce apoptosis and cell cycle arrest in cancer cells by inhibiting the PI3K-Akt-mTOR pathway, with in vivo tests confirming its efficacy in reducing tumor growth in a mouse model.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!